Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company has entered into a second collaboration with Richard K. Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin, Ireland.
SOLANA BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company has entered into a second collaboration with Richard K. Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin, Ireland.
Professor Porter’s focus will be on investigating the molecular basis of fatty acid binding protein (FABP) inhibition in cancer and the potential of the ART26.12 platform for the treatment of various tumors. Artelo believes the Trinity College research initiative will refine and expand the Company’s understanding of the role of certain FABP inhibitors and could conceivably translate into multiple compounds tailored to specific cancers from Artelo’s library of compounds.
“The potential role and implications of FABP inhibition in different forms of cancer is emerging as a very exciting and promising advancement in cancer research,” said Professor Porter. “This collaboration with Artelo will further elucidate the specific mechanisms by which targeted FABP inhibition may prevent tumor growth and halt its spreading.”
FABP plays an important role in lipid signaling and is believed to be an attractive target for cancer drug development. “Large amounts of human biomarker and animal model data support FABP as an oncology target. We believe the evidence to date suggests inhibition of FABP may be relevant in a number of different cancers with high unmet need. We are pleased to be working on a second research project with Professor Porter, who has more than 30 years experience in metabolism and bioenergetics,” said Andrew Yates, Ph.D., Artelo Biosciences’ Chief Science Officer. “The research is expected to have multiple data readouts over the next twelve months.”
About ART26.12
ART26.12 is Artelo’s platform of inhibitors to Fatty Acid Binding Proteins (FABP). FABP is an intracellular protein that chaperones lipids including endocannabinoids and fatty acids, and is intended for treatment of breast cancer, prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including post-traumatic stress disorder (PTSD). Artelo’s near-term goal is to progress its lead compound into clinical development and assess its activity in models of cancer and pain. While advancing the lead asset, additional compound(s) may be identified and selected for advancement in regulatory-enabling studies.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to Artelo’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Artelo’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Artelo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
